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Abstract  Several  mechanisms  predispose  to  bleeding  in  neoplastic  disease.  This  is  all  the  more
serious as  it  often  occurs  on  a  background  of  medically  vulnerable  patients  and  the  magnitude  of
the bleed  may  lead  to  hemorrhagic  shock  or  acute  respiratory  distress  as  a  result  of  hemoptysis.
It often  carries  a  poor  prognosis,  even  if  the  acute  episode  has  been  controlled,  as  bleeding
due to  rupture  of  a  tumor  often  indicates  an  advanced  stage  of  the  disease,  and  also  because
tumor rupture  carries  a  risk  of  metastatic  spread  including  peritoneal  carcinomatosis.  The  risk  of
recurrent  bleeding  is  also  not  insigniﬁcant.  In  most  cases,  endovascular  hemostatic  embolization
is the  ﬁrst  line  palliative  treatment.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Malignancy  is  the  leading  cause  of  death  in  France  and  is  responsible  for  approximately
30%  of  deaths  [1].  In  an  oncology  context,  progression  to  multi-organ  failure  may  occur
spontaneously  either  through  disease  progression,  by  extension  of  the  malignancy  or  more
acutely  through  infection  or  a  bleeding  or  thromboembolic  complication.  We  offer  a  review
of  the  interventional  radiology  embolization  methods  used  for  bleeding  complications  in
an  oncology  situation.Pathologic conditions predisposing to bleeding
There  are  many  and  often  concomitant  conditions  leading  to  bleeding  in  patients  with
malignancy.
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Firstly,  malignancies  themselves  are  a  risk  factor
or  coagulopathy:  neovascularization  due  to  growth
actors,  metastatic  bone  marrow  invasion,  thrombotic
icroangiopathy,  disseminated  intravascular  coagulation  or
acrophage  activation  syndrome.
Secondly,  iatrogenic  causes  are  often  involved.
hemotherapies  causing  aplasia,  prevention  of  throm-
oembolic  disease,  postoperative  pseudoaneurysms  and
 fragile  vascular  bed  following  radiotherapy  may  all  be
nvolved.
Thirdly,  a  tumor  may  have  direct  vascular  conse-
uences.  If  it  is  hypervascularized,  tumor  rupture  may
ead  to  catastrophic  bleeding.  This  applies  for  example
o  hemoperitoneum  secondary  to  rupture  of  hepatocellu-
ar  carcinomas.  The  tumor  can  erode  a  vessel,  combined
n  variable  degrees  with  mechanical  invasion  and  a  local
nﬂammatory  reaction.  In  addition  the  tumor  mass  may
bstruct  venous  circulation  causing  an  increase  in  proximal
ydrostatic  pressure,  resulting  in  varices  and  shunts  which
ay  rupture.
emoptysis
eneral details
he  severity  of  hemoptysis  is  due  to  several  factors:
nderlying  patient  circumstances,  extent,  consequences
n  coagulation  and  far  more  rarely,  hemorrhagic  shock.
alignant  tumors  are  responsible  for  approximately  30%  of
emoptyses  [2],  and  30%  of  patients  suffering  from  lung  can-
er  will  develop  hemoptysis,  10%  of  which  will  be  massive
3].
The  bronchial  arteries  are  responsible  for  over  90%  of
emoptyses  requiring  endovascular  or  surgical  intervention
4].
The  systemic  vascularization  of  the  lung  parenchyma  is
xtremely  variable  and  consists  of  bronchial  and  also  non-
ronchial  arteries.  The  so-called  modal  bronchial  arterial
rganization  consisting  of  a  right  bronchial  artery  arising
rom  a  right  broncho-intercostal  trunk  and  two  left  bronchial
rteries  arising  from  the  T5-T6  descending  thoracic  aorta
nly  account  for  25%  of  cases  [5].  In  addition  to  the  variabil-
ty  in  number  and  topography  of  these  systemic  bronchial
rteries,  interventional  radiology  also  needs  to  take  account
f  the  features  described  below.
Other  systemic  non-bronchial  arteries  may  contribute  to
ung  vascularization.  Physiologically,  the  only  other  systemic
rteries  liable  to  be  involved  are  the  arteries  from  the  area
f  the  triangular  ligament.  On  the  other  hand,  when  a  pre-
ious  history  of  pleural  disease  is  present,  symphysis  may
esult  in  recruitment  of  chest  wall  arteries.  These  have
he  speciﬁc  feature  of  not  reaching  the  lung  parenchyma
hrough  the  hilum  but  through  the  pleura.  The  presence
f  pleural  thickening  (over  3  mm)  near  the  vascular  entry
oint  is  an  indirect  sign  facilitating  their  detection  [6].  The
nferior  phrenic,  internal  thoracic  arteries  and  thyrocervical
runk  are,  for  example,  occasionally  involved.A  rich  anastomotic  network  exists  both  between  these
ronchial  arteries  and  also  with  almost  all  of  the  systemic
ediastinal  arteries.  In  lung  disease  causing  hemoptysis,
ranches  arising  from  this  network  can  be  involved  and
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ypertrophy.  This  is  a  risk  factor  for  recurrent  hemoptysis
nd  these  anastomoses  must  be  treated  during  embolization
for  example  an  interbronchial  anastomosis).
This  network  can  also  give  rise  to  ischemic  complications.
he  most  worrying  is  spinal  ischemia  due  to  accidental
mbolization  of  branches  of  the  intercostal  arteries  which
ontribute  to  the  formation  of  the  anterior  radicular  artery,
he  largest  of  which  is  the  artery  of  Adamkiewicz,  which
lso  has  very  variable  topography  [7—9].  This  arises  between
evels  T9  and  T12  in  75%  of  cases,  usually  on  the  left  (65
o  80%),  although  not  uncommonly  it  may  originate  as  high
s  level  T5.  Identifying  this  artery  during  angiography  is
herefore  recommended  before  an  embolization  procedure
s  started.  Even  where  it  is  looked  for  however,  it  is  not
lways  straightforward  to  detect  because  of  its  small  diam-
ter  and  the  intercostal  vascular  steal  effect  caused  by  the
leed  [10]. Radiologists  should  therefore  be  extremely  vig-
lant  and  examine  angiographic  images  carefully  for  any
ashout  ﬂow,  which  represents  reversal  of  the  circulation
n  these  arteries  that  supply  the  spinal  cord  [5].
Myocardial,  esophageal,  bronchial  and  tracheal  ischemia
ay  also  occur  through  the  same  mechanism.
T angiography
hest  CT  angiography  plays  a  major  role  in  the  investiga-
ion  of  hemoptyses.  The  purposes  of  this  investigation  are
o  assess  the  consequences  of  intra-alveolar  hemorrhage,  to
iagnose  underlying  disease  and  to  construct  a  pretreatment
hest  arterial  map  [11].  CT  angiography  therefore  needs  to
e  carried  out  with  sufﬁciently  concentrated  iodine  con-
rast  medium  (350  mg/dl),  delivered  at  a  sufﬁcient  ﬂow  rate
at  least  4  ml/s)  [11]. In  order  to  analyze  both  the  pul-
onary  and  systemic  vascularization,  the  image  should  be
ecorded  in  the  early  systemic  arterial  phase,  if  possible
sing  a  bolus  arrival  detector.  In  addition,  because  of  the
mall  diameter  and  considerable  variability  in  topography
f  the  arteries  examined,  thin  sections  covering  a  volume
anging  from  the  base  of  the  neck  to  the  renal  arteries  are
ssential.
Intra-alveolar  hemorrhage  appears  on  CT  as  a  combina-
ion  of  ground  glass  lesions  with  blurred  margins  and  ﬁlling
f  the  respiratory  tract  with  liquid  opaciﬁcations  [11].  These
emorrhages  may  mask  an  underlying  lesion,  particularly  a
mall  cancer  and  the  state  of  the  parenchyma  should  there-
ore  be  checked  distant  to  the  episode  of  bleeding.
The  features  of  pathological  systemic  blood  vessels
upplying  the  lung  and  therefore,  potentially  responsible
or  hemoptysis  are  a  combination  of  increased  diameter
over  2  mm)  [12], excessive  tortuosity,  a  systemic-pulmonary
hunt  and  very  occasionally,  extravasation  of  contrast
edium  [13].  The  lung  parenchyma  may  also  enhance  both
n  CT  and  on  arteriography  [14]. From  a  prognostic  perspec-
ive  however,  dilation  of  the  bronchial  arteries  correlates
oorly  with  their  risk  of  bleeding  [15].
Physiologically,  capillary  anastomoses  exist  between  the
ronchial  and  pulmonary  arteries  and  account  for  5%  of
ardiac  output  [16].  During  increased  demands  on  the  sys-
emic  vascular  system  these  communications  between  a
ow-pressure  pulmonary  network  and  a  high-pressure  sys-
emic  network  hypertrophy.  The  pressure  difference  then
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makes  the  anastomoses  fragile  and  occasionally  result  in
aneurysm  formation.
In  the  majority  of  cases,  the  target  vessel  is  a  bronchial
artery  (Fig.  1)  and  less  commonly  a  pulmonary  artery
(Fig.  2)  if  part  or  all  of  the  bleeding  is  suspected  to  arise
from  the  pulmonary  circulatory  system.  CT  therefore  guides
embolization.
Embolization
Because  of  target  vessel  size,  microcatheters  often  need  to
be  used.
Embolization  should  be  sufﬁciently  selective  to  avoid
restoring  supply  from  arterial  anastomoses  which  would  pro-
mote  recurrence  of  bleeding  and  which  is  occasionally  more
difﬁcult  to  access  by  an  endovascular  approach  [5]. The
embolization  site,  however,  must  not  be  too  peripheral  in
order  to  reduce  the  risk  of  ischemic  complications.  Con-
versely,  access  to  the  proximal  part  of  the  embolized  arterial
trunk  should  be  maintained  in  view  of  the  possibility  of  a
recurrent  bleed.
The  embolization  agents  used  are  mostly  non-resorbable
microparticles  (of  diameter  over  200  m)  and  Onyx®
[4,17,18].  The  use  of  metal  coils  alone  should  be  avoided
in  this  situation,  ﬁrstly  because  they  carry  a  risk  of  allow-
ing  anastomotic  ﬂow  to  return  from  distally  and  therefore
a  risk  of  recurrent  bleed,  and  secondly  because  they  repre-
sent  an  obstruction  if  endovascular  treatment  needs  to  be
repeated.  They  may  be  used  as  a  supplement  if  ﬂow  is  not
entirely  abolished  by  other  techniques.  It  should  be  noted
that  the  recurrence  rate  was  50%  in  the  study  published  by
Witt  et  al.,  which  used  coils  as  the  only  embolization  agent
compared  to  only  20%  reported  in  the  study  by  Garcia-Olivé
et  al.  in  which  the  radiologist  had  a  free  choice  of  materials
[19,20].
t
s
p
h
Figure 1. Severe hemoptysis not controlled by medical and endoscopi
Hilar mass developing next to the right upper lobe bronchus; b: arteriog
larization in the territory of the tumor (arrow); c: arteriography after 
intercostal artery is preserved.809
Hayakawa  et  al.  [21]  initially  suggested  that  this  tech-
ique  was  less  useful  in  the  context  of  malignancy  than
or  benign  causes  of  hemoptysis,  although  several  studies
3,19,20,22]  have  subsequently  shown  that  endovascular
mbolization  is  an  effective  palliative  treatment  for  hemop-
ysis  in  oncology.  The  two  most  recent  studies  reported
linical  success  rates  of  close  to  90%,  although  the  prog-
osis  of  these  patients  remained  poor,  with  a  64%  mortality
ate  at  one  year  [19,20].
upture of hepatocellular carcinoma
eneral details
epatocellular  carcinoma  (HCC)  is  the  third  leading  cause  of
ancer  deaths  in  the  world  [23,24].  Its  worldwide  incidence
s  increasing  because  of  the  spread  of  hepatitis  B  and  C  virus
nfections  [25,26]. This  common  cancer  is  a  public  health
roblem,  particularly  in  Eastern  Asia  and  sub-Saharan  Africa,
here  the  incidence  rates  were  36.9  and  79.4/100,000  men
n  2002  compared  to  only  1.8/100,000  men  in  Holland  [27].
Whilst  HCC  can  be  indirectly  responsible  for  bleeding
omplications  as  a  result  of  decompensation  of  underlying
irrhosis,  it  may  be  a  direct  cause  due  to  tumor  rupture.
his  is  a  relatively  rare  complication  with  reported  inci-
ences  of  3.5%  on  the  UK  and  12.4%  in  Thailand  [28,29].  It
s  however  serious  and  median  survival  is  less  than  1  month
f  the  cause  is  not  treated  [30].
The  clinical  presentation  is  typically  a combination  of
udden-onset  epigastric  or  right  hypochondrial  pain,  hem-
rrhagic  shock  and  abdominal  distention.  Occasionally  the
umor  may  rupture  into  the  biliary  tract  and  cause  a
udden-onset  picture  of  epigastric  or  right  hypochondrial
ain  associated  with  cholestasis  jaundice,  melena  and
ematemesis  [31].
c treatments in a patient with lung cancer: a: enhanced chest CT.
raphy of the right intercosto-bronchial trunk showing hypervascu-
embolization with non-resorbable 250 m diameter particles. The
810  P.  Revel-Mouroz  et  al.
Figure 2. Severe hemoptysis not controlled by medical and endoscopic treatments in a patient with hepatocellular carcinoma with lung
and mediastinal metastases: a: enhanced chest CT: cavitating hilar mass in contact with a interlobar artery near its border (arrow); b:
p ery (
A
c
v
i
t
c
s
t
s
o
h
p
w
[
s
E
E
t
a
a
b
a
c
i
a
p
t
f
I
c
f
M
O
a
t
b
b
o
t
t
c
o
f
c
t
v
a
(
r
1
m
r
t
o
p
(
i
o
t
c
p
t
c
O
W
bulmonary arteriography: laminar appearance of the interlobar art
mplatzer 12-mm diameter Plug.
The  most  widely  accepted  mechanism  for  this  compli-
ation  is  invasion  of  the  hepatic  veins  by  tumor,  impeding
enous  drainage  of  the  HCC  and  resulting  in  a  large  rise  in
ntra-tumor  pressure  and  hemorrhage,  initially  within  the
umor,  which  breaks  through  the  HCC  [32].
The  risk  factors  for  rupture  are  hypertension,  underlying
irrhosis,  large  tumors  (over  5  cm),  tumor  protrusion  on  the
urface  of  the  liver,  vascular  thrombosis  and  extra-hepatic
umor  extension  [30—33].
In  this  situation,  excision  surgery  can  only  rarely  be  con-
idered  because  of  the  many  concomitant  contraindications
f  portal  hypertension,  hepatic  encephalopathy,  ascites,
epatic  reserve  function  and  small  estimated  volume  of
ostoperative  residual  liver.  Only  6  out  of  54  patients  (11.1%)
ere  eligible  for  surgery  in  the  study  reported  by  Jin  et  al.
34].
The  alternatives  to  surgery  are  hepatic  artery  ligation,
uturing  or  packing.
mbolization
mbolization  is  likely  to  be  as  effective  and  less  damaging  in
hese  medically  vulnerable  patients,  as  it  is  less  aggressive
nd  allows  more  selective  treatment.
The  technique  involves  obtaining  peripheral  arterial
ccess  and  then  catheterizing  the  feeder  artery  to  the
leeding  tumor  as  selectively  as  possible.  The  embolization
gents  used  include  resorbable  gelatin  particles.  Convention
hemoembolization  can  also  be  carried  out  if  the  patient
s  not  hemodynamically  unstable  and  if  the  drug  is  readily
vailable  (Fig.  3).
Whilst  embolization  can  be  used  in  a  larger  population  of
atients  than  surgery,  it  also  has  its  contraindications  and
he  technique  could  only  be  used  in  52%  of  patients  rejected
or  excision  surgery  in  the  study  reported  by  Jin  et  al.  [34].
t  is  essential  to  assess  hepatic  reserve  as  the  most  serious
onsequence  of  arterial  embolization  is  hepatocellular
ailure.  Laboratory  liver  function  tests  and  Child-Pugh  or
ELD  scores  are  essential  in  the  pre-treatment  assessment.
bstructive  portal  thrombosis  is  a  contraindication  to
rterial  embolization.  If  the  biliary  tract  is  dilated  in  the
arget  segment,  the  risk  of  ischemia  and  cholangitis  has  to
b
s
marrow); c: result after obstruction of the interlobar artery with an
e  balanced  against  the  severity  of  the  bleed.  Unlike  non-
leeding  lesions,  there  is  no  consensus  on  the  management
f  these  patients  and  it  would  appear  difﬁcult  to  apply
he  Barcelona  Clinic  Liver  Cancer  guidelines  [35]  strictly
o  these  patients  as  this  is  an  immediately  life-threatening
omplication  in  the  very  short  term.
The  post-embolization  syndrome,  which  is  a  combination
f  pain,  small  spikes  of  fever,  nausea  and  vomiting  lasting  a
ew  hours  to  a  few  days  occurs  in  almost  all  patients.
Embolization  is  effective  and  controls  bleeding  in  94%  of
ases,  achieving  a  signiﬁcant  extension  of  survival  [33].  In
he  study  reported  by  Jin  et  al.  the  2-,  4-  and  6-month  sur-
ival  rates  were  better  in  the  embolization  group  (36%,  20%
nd  20%  respectively)  than  in  the  ‘‘supportive  care’’  group
8.7%  and  0%)  [34]. Median  survival  of  patients  in  the  study
eported  by  Kirikoshi  et  al.  was  224.8  days  compared  to  only
3.1  days  in  the  ‘‘conservative  treatment’’  group  [33].  The
ain  cause  of  death  in  the  control  group  in  this  study  was  a
ecurrent  bleed  (72%),  whereas  the  main  cause  of  death  in
he  embolization  group  was  hepatocellular  failure  (67%).
Poor  prognostic  indicators  after  treatment  of  the  episode
f  bleeding  are  a  raised  serum  creatinine,  the  need  for  vaso-
ressor  amines,  a  raised  bilirubin  and  a  large  tumor  size
over  7  cm  in  size)  [33,34].
The  poor  prognosis  of  ruptured  HCC  even  when  the  bleed-
ng  has  been  controlled  is  due  to  several  factors:  the  bleed
ften  indicates  locally  or  distant  advanced  stage  of  the
umor  and  decompensation  of  the  cirrhosis  is  a  common
omplication  of  bleeding.  Even  once  the  acute  episode  has
assed,  the  risk  of  peritoneal  spread  inherent  to  tumor  rup-
ure  is  sufﬁciently  high  to  represent  at  least  a  temporary
ontraindication  to  liver  transplantation  [36].
ther primary hemorrhagic liver tumors
hereas  HCC  is  by  far  the  most  common  cause  of  tumor
leeds  in  liver  disease,  the  tumor  most  commonly  responsi-
le  for  bleeding  outside  of  the  context  of  cirrhosis  is  benign,
ince  it  is  an  adenoma  [37].
Cholangiocarcinoma  is  the  second  most  common  pri-
ary  malignant  liver  tumor  and  contains  a  large  ﬁbrous
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Figure 3. Sudden-onset severe abdominal pain in a patient with clinical signs of cirrhosis: a: abdominal CT with and without enhance-
ment in the arterial phase. Dysmorphic liver with 2 hyperarterialized tumors (stars) and a hemoperitoneum. The sentinel hematoma (arrow)
in contact with the lesion in segment IV indicates the hepatocellular carcinoma responsible for the bleed; b: pre-embolization arteriog-
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araphy. Selective catheterization of the branch supplying segment 
arteriography. In the absence of hemorrhagic shock, Lipiodol tumor
component, explaining  why  bleeding  is  a  very  rare
complication  with  this  type  of  tumor.
The  potentially  hemorrhagic  primary  malignant  liver
tumors  also  include  primary  hepatic  angiosarcoma  (PHA).
This  only  represents  2%  of  primary  malignant  liver  tumors
but  it  is  the  most  common  malignant  mesenchymal  tumor,  in
front  of  epithelioid  hemangioendothelioma,  one  of  its  dif-
ferential  diagnoses,  and  other  sarcomas  [38,39].  This  is  a
richly  vascularized  tumor,  which  develops  from  sinusoid  cap-
illary  endothelial  cells.  Most  cases  are  idiopathic,  although
some  carcinogens  including  vinyl  chloride,  thorium  diox-
ide  and  arsenic  are  occasionally  implicated,  together  with
prolonged  exposure  to  anabolic  steroids.  The  male-female
sex  ratio  is  3:1.  This  disease  carries  a  poor  prognosis  and
median  survival  at  the  time  of  diagnosis  is  5  months  [40].
There  are  several  obstacles  to  its  diagnosis:  the  non-speciﬁc
clinical  presentation,  lack  of  speciﬁc  biological  marker,  vari-
able  appearances  on  imaging  (multiple  nodules,  a  single
or  predominant  mass  or  diffuse  inﬁltration  of  the  liver
parenchyma)  [40,41].  In  addition,  ultrasound  or  CT-guided
percutaneous  biopsies  are  occasionally  negative,  incorrectly
suggesting  an  alternative  histology  and  may  even  be  dan-
gerous  due  to  potential  bleeding  complications.  If  PHA  is
suspected  it  is  preferable  to  take  laparoscopic  surgical  biop-
sies.  Synchronized  metastases  are  common  and  are  typically
found  in  the  spleen  and  lungs.
Because  of  the  rich  vascularization  of  this  tumor,  it
is  not  unusual  to  encounter  spontaneous  hemorrhagic
n
o
c
pnﬁrms the presence of tumor enhancement; c: post-embolization
olization could be administered in this emergency situation.
omplications  and  in  26.6%  of  cases  the  presenting  sign  is
 hemoperitoneum,  which  may  also  recur  [42,43].  Simple
mbolization  (Fig.  4) or  chemoembolization  are  the  ﬁrst-
ine  etiological  treatments  for  a  bleeding  PHA  [44].  The  gold
tandard  treatment  in  the  absence  of  bleeding  combinations
r  after  bleeding  has  been  controlled  is  poorly  deﬁned  and
nvolves  excision  surgery,  although  this  is  rarely  possible  as
ynchronous  extra-hepatic  metastases  are  often  present.
upture of intra- and extrahepatic
etastases
econdary  liver  tumors  are  rarely  responsible  for  bleeding
ompared  to  primary  liver  tumors.  Whilst  bleeding  metas-
ases  from  many  primary  tumors  have  been  described,  lung
nd  renal  carcinomas  and  melanomas  are  the  tumors  that
ost  often  cause  bleeding  [45].  This  situation  is  far  rarer
lthough  it  is  managed  differently  to  the  HCC  as  no  underly-
ng  liver  disease  is  present.  In  the  case  of  a  hemoperitoneum
owever,  these  patients  also  have  a  poor  prognosis  and
lmost  none  survive  over  6  months  [46].
Given  the  rarity  of  bleeding  liver  metastases,  a  relatively
on-speciﬁc  clinical  presentation  with  variable  proportions
f  shock,  sudden-onset  severe  abdominal  pain  and  a  surgi-
al  abdomen  points  towards  differential  diagnoses  such  as  a
erforated  peptic  ulcer  [47].  Imaging  can  occasionally  reﬁne
812  P.  Revel-Mouroz  et  al.
Figure 4. Spontaneous bleeding of a hepatic angiosarcoma: a: abdominal CT before and after contrast enhancement. Heterogeneous
hypovascularized mass with blood lakes (arrow) combined with an intrahepatic hematoma (star); b: in the arterial phase (left image),
arteriography shows predominantly peripheral enhancement appearing as blood lakes. In the venous phase (right image) the avascular zone
(arrow) persists and shows the intra-hepatic hematoma; c: post-treatment appearances after embolization with resorbable particles.
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che  diagnosis  by  showing  a  bleeding  liver  lesion,  sponta-
eous  sub-capsular  hematoma,  hemoperitoneum  or  primary
umor.
In  common  with  the  HCC,  the  diagnosis  can  occasionally
e  supported  by  active  extravasation  contrast  medium,  and
n  some  cases  a  heterogeneous  collection  contiguous  with
he  lesion  with  a  density  of  50—60  Hounsﬁeld  units  indicates
 sentinel  clot  and  therefore  a  recent  bleed  [45—49].
Extrahepatic  metastases  can  also  rupture  and  cause
ntraperitoneal  or  retro-peritoneal  hemorrhage  or  bleeding
nto  the  gastrointestinal  or  urinary  tract.  The  histological
umor  types  responsible  are  the  same  as  for  intrahepatic
isease.  These  are  relatively  non-speciﬁc  and  the  ﬁrst-line
reatment  of  uncontrolled  bleeding  is  also  endovascular
mbolization  (Fig.  5).
The  diagnosis  is  considerably  easier  when  prior  imaging
hows  a  pre-existing  metastasis.
upture of a retroperitoneal tumor
his  is  a  rare  pathological  condition.  Zhang  et  al.  reported
01  cases  of  spontaneous  perirenal  hemorrhage  in  a  meta-
nalysis  based  on  English-language  publications  between
985  and  1999  [50].  In  decreasing  orders  of  frequency  the
auses  of  spontaneous  perirenal  hematoma  are  angiomy-
lipomas,  renal  cell  carcinomas  and  polyarteritis  nodosa
50—52].  Clinical  symptoms  are  non-speciﬁc  and  include
enk’s  triad,  which  is  a  combination  of  sudden-onset  uni-
ateral  lumbar  pain,  lumbar  swelling  and  hemodynamic
bnormalities  and  is  present  in  50%  of  cases.  Hematuria
s  often  absent  [52,53].  The  pathophysiological  mechanism
nvolving  rupture  of  a  renal  tumor  is  poorly  understood.
ngimyolipomas  and  renal  cell  carcinomas  have  the  speciﬁc
eature  of  being  richly  vascularized,  which  appears  to  be risk  factor  for  bleeding.  Papillary  carcinoma,  the  second
ost  common  subtype  of  renal  cell  carcinoma  in  order  of
requency  after  clear  cell  carcinoma  very  rarely  bleeds,  as
t  is  hypovascularized  [54,55].
r
r
p
aSome  authors  have  attributed  the  cause  of  a  bleed  to
irect  erosion  of  the  renal  vessels  or  renal  capsule  by  the
umor,  whereas  others  have  suggested  that  in  the  same  way
s  for  HCC,  venous  invasion  causes  a  rise  in  pressure  within
he  tumor,  predisposing  to  rupture.  In  addition,  tumor  rup-
ure  occurring  during  hemodialysis  may  be  attributable  to
he  anticoagulation  required  because  of  the  extracorporeal
irculation  [56].
The  investigation  of  choice  in  this  urgent  situation  is
omputed  tomography  [57]. Identifying  a  tumor  underlying
 perirenal  hematoma  may  be  difﬁcult,  as  the  volume  of
he  hematoma  often  masks  small  tumors.  This  process  is
ade  even  more  difﬁcult  when  concomitant  acquired  poly-
ystic  disease  is  present  in  the  dialyzed  kidney.  This  has  a
revalence  of  33%  in  patients  with  end-stage  renal  failure,
articularly  as  these  patients  are  at  risk  of  malignancy,  as
he  prevalence  of  renal  cell  cancers  in  this  group  is  4.2%
58].
Irrespective  of  the  underlying  disease,  renal  emboliza-
ion  is  the  ﬁrst  line  emergency  treatment  if  the  bleeding
s  poorly  tolerated  clinically  (Fig.  6).  This  often  succeeds
n  obtaining  hemostatic  embolization  and  can  identify  the
esion  responsible.  If  it  fails,  the  ultimate  recourse  is  hemo-
tatic  nephrectomy.
Subsequent  treatment  is  guided  by  the  cause.  It  is  impor-
ant  to  highlight  that  if  no  cause  is  found  on  radiological
nvestigations  it  is  highly  likely  that  a malignant  tumor  is
resent.  Caution,  regular  monitoring  and  even  nephrectomy
re  required  [59,60].
Spontaneous  ruptures  of  pheochromocytomas  are  also
xtremely  rare  but  have  a  mortality  rate  of  32%  [61].  This
s  explained  not  only  by  the  risk  of  bleeding  but  also  and
articularly  at  the  risk  of  potentially  fatal  catecholamine
elease  as  a  result  of  surgery.  Excision  surgery  requires
areful  patient  preparation  with  non-selective  adrenergic
eceptor  antagonists  in  order  to  stabilize  blood  pressure  and
educe  the  risk  of  cardiac  arrhythmia  [62,63].  If  it  is  not
ossible  to  prepare  the  patient  before  excision  surgery  for
 ruptured  pheochromocytoma,  the  mortality  rate  reaches
Hemostastic  embolization  in  oncology  813
Figure 5. Rupture of spleen metastases of a melanoma: a: abdominal CT without enhancement. Subcapsular splenic hematoma in contact
with a spontaneously hypointense intraparenchymal mass (star); b: splenic arteriography. Hypovascular mass in the inferior pole of the
spleen appearing as a spur sign; c: splenic arteriography. Post-treatment appearance after proximal obstruction of the splenic artery with
coils analogous to the preventative embolization technique for traumatic injury to the spleen at high risk of rupture. Proximal embolization
reduces the intrasplenic pressure and avoids infarction because of collateral supply from the gastro-epoploic and pancreatic arcades.
Figure 6. Renal cell cancer presenting with hemorrhagic shock: a: CT after contrast enhancement, axial and coronal view. Clearly
delineated mass on the external border of the left kidney, which is hypovascularized and surrounded by a large hemoperitoneum; b:
shows
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fhemostatic embolization. Pre-procedure angiography (left image) 
branch after embolization on the right (non-resorbable particles an
44.7%  [64].  Embolization  is  also  the  treatment  of  choice  for
a  bleeding  pheochromocytoma  as  it  allows  planned  excision
surgery  to  be  carried  out.
Hematuria and bladder cancerMacroscopic  hematuria,  which  is  classically  painless  and
occurs  at  the  end  of  voiding,  is  the  presenting  symptom
of  bladder  cancer  in  almost  80%  of  cases  [65]  and  can  also
occur  during  the  natural  history  of  the  disease  after  its  initial
t
a
p rich tumor neovascularization. Interruption of ﬂow in the tumor
ls).
tages.  The  causes  of  hematuria  in  this  situation  are  multi-
le  and  often  interlinked:  primary  tumor  bleed,  radiation
r  chemical  cystitis,  severe  infection  or  the  co-existence  of
ther  pelvic  cancers  [66].  The  bleed  is  also  maintained  by
he  anti-coagulant  effect  of  urokinase.  The  consequences
f  hematuria  may  be  a  globus  vesicalis,  obstructive  renal
ailure  or  even  hemorrhagic  shock.Many  treatments  can  be  used  for  these  cases  of  hema-
uria,  including  oral  administration  of  —aminocaproic
cid,  intravesical  irrigation  with  alum,  instillations  of
rostaglandins,  fractionated  radiotherapy,  bladder  diversion
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B14  
nd  palliative  excision.  Despite  this  wide  range  of  meth-
ds  used,  controlled  studies  providing  a  solid  basis  for  the
pproaches  to  treatment  are  lacking.  Interventional  radiol-
gy  offers  two  techniques:  embolization  and  intra-arterial
hemotherapy  with  mitoxantrone.  These  have  the  com-
on  feature  of  not  requiring  general  anesthesia.  They  also
nvolve  a  similar  vascular  approach,  puncturing  the  common
emoral  artery  followed  by  cross-catheterization  using  the
eldinger  Technique,  with  the  aim  of  selectively  catheteriz-
ng  the  anterior  dividing  trunk  of  the  internal  iliac  artery  in
rder  to  spare  the  superior  gluteal  branches  [67,68].  The
mbolization  agents  used  in  preference  should  allow  the
rocedure  to  be  repeated  if  the  bleeding  recurs.  Wherever
ossible,  therefore,  metal  coils  should  be  avoided.  The  most
ommon  complications  are  pain  in  the  gluteal  region  and
emporary  urinary  disturbances.  Lasynecrosis  is  the  most
orrying  complication,  although  this  has  only  been  reported
n  cases  of  severe  pelvic  trauma  [66—69].
Intra-arterial  chemotherapy  involves  an  intra-arterial
nfusion  of  mitoxantrone  at  a  dose  of  20  mg/m2 body  surface
rea,  over  a  period  of  1  to  2  hours,  which  may  be  repeated
70].
Textor  et  al.  compared  the  two  techniques  in  a  non-
andomized  study  [69].  Although  the  bleeding  control  (80
nd  93.3%)  and  recurrence  rates  (21.4  and  30.8%)  were
imilar  in  both  groups,  severe  complications  only  occurred
n  the  ‘‘embolization’’  arm  and  post-treatment  pain  was
lso  more  common  in  this  group  (90.9%  versus  19.4%  in
he  ‘‘chemotherapy’’  arm).  On  the  other  hand,  the  time
equired  to  achieve  control  of  the  bleeding  was  less  than
4  hours  in  the  ‘‘embolization’’  group  compared  to  4  to
5  days  in  the  ‘‘chemotherapy’’  group  [69].  It  appears  there-
ore  that  embolization  is  an  appropriate  technique  for
cute,  life-threatening  hematuria,  whereas  chronic  hema-
uria  can  be  treated  by  intra-arterial  chemotherapy.  No
tudies  have  described  the  combination  of  this  technique
ith  intra-arterial  chemoembolization.
rterio-ureteric ﬁstula
he  incidence  of  this  disease  is  increasing  and  is  probably
nderestimated.  Risk  factors  for  an  arterio-ureteric  ﬁstula
re  a  previous  history  of  abdominal  or  pelvic  oncologic  or
ascular  surgery,  urinary  shunt  surgery,  prolonged  use  of  a
ladder  catheter,  a  previous  history  of  radiotherapy  or  a
ascular  stent  [71].  By  far  the  most  common  site  of  these  ﬁs-
ulae  is  the  crossover  point  between  the  iliac  artery  and  the
reter.  In  this  area  the  proximity  of  these  structures  make
heir  walls  vulnerable  to  inﬂammatory  and  ﬁbrotic  reactions
V
h
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nd  where  relevant,  radiation  vasculitis,  all  of  which  are
esponsible  for  ﬁstula  formation  [72]. Although  this  is  a  rare
ondition  it  is  important  not  to  miss  its  possible  diagnosis,
s  the  disease-speciﬁc  mortality  without  treatment  is  58%
nd  a  delay  in  diagnosis  is  a  major  poor  prognostic  indicator
71—73].
The  predominant  symptom  is  hematuria,  which  occurs  in
ll  patients  and  may  be  either  microscopic  or  macroscopic.
lthough  it  is  often  not  particularly  heavy  but  is  recurrent,
t  may  involve  catastrophic  bleeding.  Hematuria  is  the  only
ymptom  in  74%  of  cases  and  is  combined  with  lumbar  pain
r  signs  of  infection  in  17%  and  7%  of  cases  respectively  [71].
The  diagnosis  can  occasionally  be  made  by  the  usual
nvestigations  carried  out  for  hematuria,  although  only  a
mall  percentage  of  conventional  investigations  are  contrib-
tory  (42%  for  CT,  14%  for  ultrasound  and  4%  of  cystoscopy)
71].
The  reference  diagnostic  investigation  preferred  over
irect  urinary  tract  opaciﬁcation  methods  is  iliac  arte-
iography  (Fig.  7).  It  is  important  to  be  aware  of  this
peciﬁc,  rare  and  often  missed  condition,  as  diagnostic
rrors  can  lead  to  a  hemostatic  nephrectomy  being  per-
ormed,  whereas  endovascular  treatment  (usually  with  a
oated  stent)  achieves  excellent  results  [71].
are malignant causes
e  also  describe  below  three  causes  of  severe  bleeding  in  a
ontext  of  malignancy.
ervical cancer
lthough  metrorragia  is  a common  presenting  feature  of
ervical  cancer,  it  is  extremely  rare  for  this  to  be  hemo-
ynamically  threatening  (Fig.  8).
egmental portal hypertension
dvanced  pancreatic  cancer  often  causes  segmental  portal
ypertension  due  to  invasion  of  either  the  splenic  or  supe-
ior  mesenteric  vein.  The  gastric  or  duodenal  varices  caused
arry  a  rare  but  existent  risk  of  gastrointestinal  hemorrhage
Fig.  9).
udd-Chiari syndromeery  occasionally,  extensive  tumor  disease  may  compromise
epatic  venous  drainage  and  cause  true  post-sinusoidal
ntrahepatic  portal  hypertension  (Fig.  10).
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Figure 7. Macroscopic hematuria in a female patient with a previous history of cervical cancer with radiation-induced ureteric damage
treated by long-term ureteric bypass: a: CT after enhancement, axial view performed at that time of the bleed not shown extravasation of
vascular contrast to the ureters; b: CT after enhancement with volume reconstruction showing the anatomical relationships of the ureteric
catheters and two iliac arteries; c: hemostatic embolization. Arteriography shows the ﬁstula between the origin of the right external iliac
artery and the ureter (arrow). After deploying a coated stent the arterio-uroteric ﬁstula is abolished.
816  P.  Revel-Mouroz  et  al.
Figure 8. Irretractable metrorrhagia due to cervical cancer: a: CT after enhancement. Hypovascularized inﬁltrating mass next to the
cervix; b: tumor enhancement during selective catheterization of the left uterine artery; c: devascularization of the tumor after embolization
(non-resorbable particles and coils).
Figure 9. Recurrent hematemesis in a patient with locally advanced pancreatic adenocarcinoma: endoscopically the bleeding is
attributable to duodenal varices: a: enhanced CT axial view (upper image) and frontal MIP reconstruction (lower image). The tumor creates
a sheath around the superior mesenteric artery and the mesenteric vein cannot be seen (arrow head), a large intra and peri-pancreatic
cavenoma allows reinjection into the portal trunk (white arrow); b: portal recanalizations. Transparietal transhepatic portography (left
image) conﬁrms stenosis of the portal trunk (arrow). After passing the obstruction, the opaciﬁcation of the mesenteric vein correlates
well with the CT MIP reconstruction (central image). After deploying a metal stent (right image), the superior mesenteric ﬂow is diverted
preferentially to the portal trunk.
Hemostastic  embolization  in  oncology  817
Figure 10. Recurrent hematemesis due to rupture of esophageal varices in the patient with colonic carcinoma and liver extension: a:
enhanced CT, axial view (upper image) and frontal MIP reconstruction (lower image). Extensive hepatic tumor inﬁltration with obstruction
of the right and middle hepatic veins and ostial stenosis of the left hepatic vein (arrow); b: left hepatic vein angioplasty through the jugular
vein. Deployment of a metal stent releases the proximal stenosis.
8 P.  Revel-Mouroz  et  al.
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Arterio-ureteric  ﬁstulae
• Risk  factors:  previous  history  of  abdominal  or
pelvic  oncologic  or  vascular  surgery,  urinary  tract
bypass  surgery,  prolonged  use  of  a  bladder  catheter,
previous  history  of  radiotherapy  or  vascular  stent.
• Topography:  the  cross-over  between  the  ileac  vessels
and  the  ureters.
• Embolization  with  coated  stent.
Indirect  venous  mechanism
• Far rarer  than  tumor  ruptures.
• Examples:  segmental  portal  hypertension  from
pancreatic  or  bile  duct  cancers,  Budd-Chiari
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iliac  arteriography  is  required.18  
onclusion
leeding  complications  in  a  context  of  malignancy  have
any  and  often  interlinked  causes.  The  immediate  risk
s  the  extent  of  the  hemorrhage  or  its  consequences  on
he  functioning  of  an  organ.  When  the  hemorrhage  is
ue  to  tumor  rupture;  it  also  carries  a  risk  of  secondary
eeding.
In  addition  to  non-speciﬁc  resuscitation  measures,  inter-
entional  radiology  is  often  the  ﬁrst  line  hemostatic
reatment.
Take-home  messages
Context
• Hemorrhages  are  rare  but  serious  complications  of
neoplastic  lesions.
• The  mechanism  most  commonly  involved  is  tumor
rupture.
• Generally,  risk  correlates  with  the  extent  of
neovascularization  and  tumor  extension.
Hemoptysis
• Complicates  30%  of  lung  cancers,  10%  involve  massive
hemoptyses.
• The  systemic  arteries  are  far  more  often  involved
than  the  pulmonary  arteries.
• Embolization  should  be  with  particles  over  200    in
size  to  avoid  paradoxical  emboli.
• Spinal  ischemia  is  the  most  worrying  complication.
HCC
• Limited  surgical  options  because  of  the  background
of  underlying  cirrhosis.
• Embolization  with  resorbable  particles  or
chemoembolization.
• The  most  serious  complication  is  hepatocellular
failure  and  hepatic  reserve  needs  to  be  assessed
before  the  procedure.
• Relative  contraindications:  hepatofugal  portal  ﬂow,
biliary  tract  dilation.
Bladder  cancer  and  hematuria
• No  consensus  treatment  indications
• Embolization  is  effective  for  rapid  control  of
bleeding.
• Intra-arterial  chemotherapy  is  suitable  for  chronic
hematuria.
Retroperitoneal  tumors
• Embolization  is  particularly  useful  for  ruptured
pheochromocytomas,  enabling  planned  surgery.
Metastases• The  most  common  primaries:  lung,  kidney,
melanoma.
3Syndrome  due  to  compression  of  the  hepatic  veins.
• Treatment  is  with  angioplasty.
linical Case
his  72-year-old  woman  presents  with  massive  rectal  bleed-
ng  and  macroscopic  hematuria,  both  through  the  right
ephrostomy  tube  and  urethra.
This  is  a  patient  hospitalized  in  urology  with  a  previous
istory  of  cervical  cancer,  treated  by  pelvic  radiotherapy
nd  complicated  by  right  ureteric  stenosis,  which  required
urgical  re-implantation  protected  by  a  nephrostomy.  The
pisode  occurred  immediately  after  a  failure  to  change  the
ouble  J  stent.
uestions
.  You  carry  out  an  urgent  abdominal  and  pelvic  scan  with-
out  and  then  with  enhancement  in  the  arterial  phase
(Fig.  11a  and  b).  What  is  your  diagnosis  from  the  images
provided  to  you?  Justify  your  answer.
.  If  the  CT  scan  had  been  negative  and  showed  no  other
abnormalities,  could  you  have  excluded  this  diagnosis?
What  would  then  be  the  most  appropriate  investigation?
.  What  treatment  would  you  propose?
nswers
.  This  is  a right  common  iliac  artery  ﬁstula,  with  both  the
gastro-intestinal  and  urinary  tracts.  In  the  arterial  phase,
the  endoluminal  enhancement  of  the  right  ureter,  last
loop  of  ileum  and  caecum  indicate  heavy  active  bleeding.
.  No,  a  negative  CT  does  not  exclude  the  diagnosis.
Because  of  the  patient’s  unstable  hemodynamic  state,.  Endovascular  embolization  of  the  arterial  ﬁstula
(Fig.  11c)  can  be  carried  out  at  the  stage  of  the
diagnostic  arteriography.  Deploying  a  coated  stent.
Hemostastic  embolization  in  oncology  819
Figure 11. a: abdominal and pelvic CT (upper image) then with contrast enhancement in the arterial phase (lower image); b: abdominal
liqueand pelvic CT with contrast enhancement in the arterial phase. Ob
(left image) and post-treatment appearances (right image).
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